These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8116353)

  • 1. Low dose intranasal nafarelin for the treatment of endometriosis.
    Jacobson J; Harris SR; Bullingham RE
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):144-50. PubMed ID: 8116353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with nafarelin for endometriosis in young women. Efficacy, safety and lipid metabolism. Niigata Nafarelin Study Group.
    Kurabayashi T; Takakuwa K; Tanaka K
    J Reprod Med; 2000 Jun; 45(6):454-60. PubMed ID: 10900577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density.
    Hornstein MD; Yuzpe AA; Burry K; Buttram VC; Heinrichs LR; Soderstrom RM; Steinberger E; Lin JS
    Fertil Steril; 1997 Jun; 67(6):1013-8. PubMed ID: 9176437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.
    Agarwal SK; Hamrang C; Henzl MR; Judd HL
    J Reprod Med; 1997 Jul; 42(7):413-23. PubMed ID: 9252932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain of endometriosis: effects of nafarelin and danazol therapy.
    Adamson GD; Kwei L; Edgren RA
    Int J Fertil Menopausal Stud; 1994; 39(4):215-7. PubMed ID: 7951404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).
    Tahara M; Matsuoka T; Yokoi T; Tasaka K; Kurachi H; Murata Y
    Fertil Steril; 2000 Apr; 73(4):799-804. PubMed ID: 10731543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.
    Finkelstein JS; Arnold AL
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1214-9. PubMed ID: 10199756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of treating endometriosis with nafarelin].
    Marianowski L; Kamiński P
    Wiad Lek; 1994 Aug; 47(15-16):595-7. PubMed ID: 7716957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).
    Adamson GD; Heinrichs WL; Henzl MR; Yuzpe AA; Bergquist C; Jacobson JJ; Eriksson S; Kwei L; Gilbert SM
    Am J Obstet Gynecol; 1997 Dec; 177(6):1413-8. PubMed ID: 9423744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis.
    Bergqvist A;
    Gynecol Endocrinol; 2000 Dec; 14(6):425-32. PubMed ID: 11228063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.
    Bergqvist A; Jacobson J; Harris S
    Gynecol Endocrinol; 1997 Jun; 11(3):187-94. PubMed ID: 9209899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafarelin in the treatment of endometriosis. Dose management.
    Hull ME; Barbieri RL
    Gynecol Obstet Invest; 1994; 37(4):263-4. PubMed ID: 8050732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.
    Henzl MR; Corson SL; Moghissi K; Buttram VC; Berqvist C; Jacobson J
    N Engl J Med; 1988 Feb; 318(8):485-9. PubMed ID: 2963213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafarelin therapy in endometriosis: long-term effects on bone mineral density.
    Orwoll ES; Yuzpe AA; Burry KA; Heinrichs L; Buttram VC; Hornstein MD
    Am J Obstet Gynecol; 1994 Nov; 171(5):1221-5. PubMed ID: 7977523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).
    Fertil Steril; 1992 Mar; 57(3):514-22. PubMed ID: 1531464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis].
    Palatyński A; Gruszczyńska J; Sobkiewicz S
    Ginekol Pol; 2001 May; 72(5):284-9. PubMed ID: 11526758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study.
    Audebert A; Descamps P; Marret H; Ory-Lavollee L; Bailleul F; Hamamah S
    Eur J Obstet Gynecol Reprod Biol; 1998 Aug; 79(2):145-8. PubMed ID: 9720832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
    Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
    Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
    Raitz von Frentz M; Schweppe KW
    Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.